治疗隐球菌性脑膜炎患者的药物获取。
Access to Medicines for Treating People With Cryptococcal Meningitis.
机构信息
MSF Access Campaign, Médecins Sans Frontières, Geneva, Switzerland.
Global HIV, Hepatitis and STIs Programme, World Health Organization, Geneva, Switzerland.
出版信息
Clin Infect Dis. 2023 Feb 8;76(3):e773-e775. doi: 10.1093/cid/ciac689.
Abstract
Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.
摘要
新型隐球菌脑膜炎占全球与艾滋病相关死亡人数的 1/5。世界卫生组织的指导方针强烈建议使用单剂量高浓度脂质体两性霉素 B 作为首选治疗方法的一部分，但在大多数中低收入国家，这种药物仍然负担不起。制造商和其他利益相关者需要采取积极主动的方法来改善获取途径。
Zotero 插件